Skip to main content
Premium Trial:

Request an Annual Quote

Bristol-Myers Squibb, Meso Scale Discovery Developing Assays for Alzheimer's Research

NEW YORK (GenomeWeb News) – Bristol-Myers Squibb and Meso Scale Discovery today announced a deal to develop assays for use in Alzheimer's disease research.

The assays, which will measure biomarkers in cerebrospinal fluid, will be based on the Meso Scale Discovery Multi-Array technology platform. The technology consists of proprietary patterned arrays and electrochemiluminescence detection and enables "large number of measurements with exceptional sensitivity, wide dynamic range, and convenience," according to Meso Scale Discovery, a division of Meso Scale Diagnostics.

Meso Scale Discovery, based in Gaithersburg, Md., plans to commercialize the assays for Alzheimer's research and drug development in the second quarter.

"These assays could provide the Alzheimer's disease research community with an important tool to help advance understanding of this complex and devastating disease and may lead to advances in the diagnosis and treatment of Alzheimer's disease," Jane Tiller, vice president of global clinical research for Bristol-Myers Squibb, said in a statement.

Financial and other terms were not disclosed.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.